(Q35873775)

10 August 2017

1 reference

title

Monoclonal antibodies for brain tumour treatment (English)

1 reference

10 August 2017

1 reference

6

Darell D Bigner

1 reference

10 August 2017

5

David A Reardon

1 reference

10 August 2017

Abraham Boskovitz

1

1 reference

10 August 2017

Carol J Wikstrand

series ordinal

2

1 reference

10 August 2017

Chien-Tsun Kuan

series ordinal

3

1 reference

10 August 2017

Michael R Zalutsky

series ordinal

4

1 reference

10 August 2017

language of work or name

English

0 references

publication date

1 September 2004

1 reference

Expert Opinion on Biological Therapy

10 August 2017

published in

1 reference

10 August 2017

volume

4

1 reference

10 August 2017

issue

9

1 reference

10 August 2017

page(s)

1453-1471

1 reference

Continuous cultures of fused cells secreting antibody of predefined specificity

10 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.9.1453

Tumor antigens in astrocytic gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.9.1453

Tenascin expression in human glioma cell lines and normal tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.9.1453

Identification of a glioblastoma-associated tenascin-C isoform by a high affinity recombinant antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.9.1453

Focal adhesion integrity is downregulated by the alternatively spliced domain of human tenascin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.9.1453

Phase II trial of murine (131)I-labeled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.9.1453

Locoregional radioimmunotherapy in selected patients with malignant glioma: experiences, side effects and survival times

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.9.1453

Phase I study of the humanized antiepidermal growth factor receptor monoclonal antibody EMD72000 in patients with advanced solid tumors that express the epidermal growth factor receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.9.1453

Relationship between gene amplification and chromosomal deviations in malignant human gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.9.1453

EGF mutant receptor vIII as a molecular target in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.9.1453

Clinical immunotherapy for brain tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.9.1453

Role of an anti-epidermal growth factor receptor in treating cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.9.1453

Unarmed, tumor-specific monoclonal antibody effectively treats brain tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.9.1453

Increased binding affinity enhances targeting of glioma xenografts by EGFRvIII-specific scFv

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.9.1453

A monoclonal antibody recognizing human cancers with amplification/overexpression of the human epidermal growth factor receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.9.1453

Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.9.1453

Neural cell recognition molecule L1: relating biological complexity to human disease mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.9.1453

A comparison of targeting of neuroblastoma with mIBG and anti L1-CAM antibody mAb chCE7: therapeutic efficacy in a neuroblastoma xenograft model and imaging of neuroblastoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.9.1453

Evaluation of radioiodinated and radiocopper labeled monovalent fragments of monoclonal antibody chCE7 for targeting of neuroblastoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.9.1453

21 January 2018

Endocytosis via caveolae

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.9.1453

Location is everything: lipid rafts and immune cell signaling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.9.1453

The glioma-associated gangliosides 3'-isoLM1, GD3 and GM2 show selective area expression in human glioblastoma xenografts in nude rat brains.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.9.1453

Targeted radioimmunotherapy for leptomeningeal cancer using (131)I-3F8.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.9.1453

Anti-VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.9.1453

Potent VEGF blockade causes regression of coopted vessels in a model of neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.9.1453

Monoclonal antibodies to vascular endothelial growth factor (VEGF) and the VEGF receptor, FLT-1, inhibit the growth of C6 glioma in a mouse xenograft.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.9.1453

Pharmacokinetic characteristics and biodistribution of radioiodinated chimeric TNT-1, -2, and -3 monoclonal antibodies after chemical modification with biotin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.9.1453

Rituximab and other emerging antibodies as molecular target-based therapy of lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.9.1453

Transferrin receptor ligand-targeted toxin conjugate (Tf-CRM107) for therapy of malignant gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.9.1453

Efficacy of direct intratumoral therapy with targeted protein toxins for solid human gliomas in nude mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.9.1453

MRP3, an organic anion transporter able to transport anti-cancer drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.9.1453

Characterization of the human multidrug resistance protein isoform MRP3 localized to the basolateral hepatocyte membrane

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.9.1453

cDNA cloning and inducible expression of human multidrug resistance associated protein 3 (MRP3)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.9.1453

In vitro and in vivo cytotoxic activities of recombinant immunotoxin 8H9(Fv)-PE38 against breast cancer, osteosarcoma, and neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.9.1453

Pharmacokinetics and biodistribution of genetically engineered antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.9.1453

Dose escalation with repeated intrathecal injections of 131I-labelled MAbs for the treatment of central nervous system malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.9.1453

Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.9.1453

Chimeric antibody: potential applications for drug delivery and immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.9.1453

Chimeric anti-tenascin antibody 81C6: increased tumor localization compared with its murine parent.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.9.1453

Replacing the complementarity-determining regions in a human antibody with those from a mouse

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.9.1453

Reshaping human antibodies for therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.9.1453

Human antibodies by design

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.9.1453

Antibody engineering via genetic engineering of the mouse: XenoMouse strains are a vehicle for the facile generation of therapeutic human monoclonal antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.9.1453

Catabolism of radioiodinated murine monoclonal antibody F(ab')2 fragment labeled using N-succinimidyl 3-iodobenzoate and Iodogen methods

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.9.1453

Human/murine chimeric 81C6 F(ab')(2) fragment: preclinical evaluation of a potential construct for the targeted radiotherapy of malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.9.1453

Isolation of picomolar affinity anti-c-erbB-2 single-chain Fv by molecular evolution of the complementarity determining regions in the center of the antibody binding site

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.9.1453

Clinical evidence of efficient tumor targeting based on single-chain Fv antibody selected from a combinatorial library

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.9.1453

Design and application of diabodies, triabodies and tetrabodies for cancer targeting

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.9.1453

In vivo comparison of macrocyclic and acyclic ligands for radiolabeling of monoclonal antibodies with 177Lu for radioimmunotherapeutic applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.9.1453

Astatine-211-labeled radiotherapeutics: an emerging approach to targeted alpha-particle radiotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.9.1453

Improved xenograft targeting of tumor-specific anti-epidermal growth factor receptor variant III antibody labeled using N-succinimidyl 4-guanidinomethyl-3-iodobenzoate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.9.1453

N-succinimidyl 3-[211At]astato-4-guanidinomethylbenzoate: an acylation agent for labeling internalizing antibodies with alpha-particle emitting 211At

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.9.1453

Antibody-guided three-step therapy for high grade glioma with yttrium-90 biotin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.9.1453

Pretargeted adjuvant radioimmunotherapy with yttrium-90-biotin in malignant glioma patients: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.9.1453

Immunotoxin therapy for CNS tumor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.9.1453

Progress report of a Phase I study of the intracerebral microinfusion of a recombinant chimeric protein composed of transforming growth factor (TGF)-alpha and a mutated form of the Pseudomonas exotoxin termed PE-38 (TP-38) for the treatment of malig

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.9.1453

Multiple infusions of anti-epidermal growth factor receptor (EGFR) monoclonal antibody (EMD 55,900) in patients with recurrent malignant gliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.9.1453

Malignant astrocytomas treated with iodine-125 labeled monoclonal antibody 425 against epidermal growth factor receptor: A phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.9.1453

Radioimmunotherapy as a novel treatment regimen: 125I-labeled monoclonal antibody 425 in the treatment of high-grade brain gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.9.1453

Controlled modulation of BBB permeability using the bradykinin agonist, RMP-7.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.9.1453

Pharmacokinetics and acute toxicology of intraventricular 131 I-monoclonal antibody targeting disialoganglioside in non-human primates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.9.1453

Convection-enhanced delivery of macromolecules in the brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.9.1453

Intratumoral infusion of the monoclonal antibody, mAb 425, against the epidermal-growth-factor receptor in patients with advanced malignant glioma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.9.1453

Role of nuclear medicine in the treatment of malignant gliomas: the locoregional radioimmunotherapy approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.9.1453

Iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with recurrent malignant gliomas: phase I trial results

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.9.1453

Phase I trial results of iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with newly diagnosed malignant gliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.9.1453

Dosimetry and dose-response relationships in newly diagnosed patients with malignant gliomas treated with iodine-131-labeled anti-tenascin monoclonal antibody 81C6 therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.9.1453

Production of functional chimaeric mouse/human antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.9.1453

10.1517/14712598.4.9.1453

21 January 2018

Identifiers

DOI

1 reference

10 August 2017

1 reference